½ÃÀ庸°í¼­
»óǰÄÚµå
1701891

·¹ÀÌÀú ĸó Çö¹ÌÇØºÎ(LCM) ½ÃÀå : Á¦Ç°º°, ½Ã½ºÅÛ À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)

Laser Capture Microdissection Market Report by Product, System Type, Application, End User (Hospitals, Academic and Government Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations ), and Region 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 139 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

·¹ÀÌÀú ĸó Çö¹ÌÇØºÎ(LCM) ½ÃÀå ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 1¾ï 6,200¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ÀÌ ½ÃÀåÀÌ 2033³â±îÁö 3¾ï 4,600¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025³âºÎÅÍ 2033³â±îÁö 8.8%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¾Ï ¿¬±¸ÀÇ È®´ë, ¹ÙÀÌ¿À¸¶Ä¿ Ž»öÀÇ °ý¸ñÇÒ¸¸ÇÑ ¼ºÀå, ÀǾàǰ °³¹ßÀÇ ¹ßÀüÀÌ ½ÃÀå °³Ã´À» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

·¹ÀÌÀú ĸó Çö¹ÌÇØºÎ(LCM)Àº ·¹ÀÌÀú ºö°ú Çö¹Ì°æ¿¡ ÀÇÇÑ Á÷Á¢ ½Ã°¢È­¸¦ ÀÌ¿ëÇÏ¿© ÁÖº¯ Á¶Á÷¿¡¼­ ¼¼Æ÷¸¦ ºÐ¸®ÇÏ´Â °íÇØ»óµµ ±â¹ýÀÔ´Ï´Ù. Á¶Á÷, Ç÷¾×, Á¤¾× »ùÇÿ¡¼­ ¼ø¼öÇÑ ³óÃà ¼¼Æ÷ Áý´ÜÀ» äÃëÇϱâ À§ÇØ Àڿܼ±(UV), Àû¿Ü¼±, ¸é¿ª Çü±¤ ·¹ÀÌÀú ±¤¼±À» ÀÌ¿ëÇÕ´Ï´Ù. Á¤»ó ¼¼Æ÷¿Í ºñÁ¤»ó ¼¼Æ÷¸¦ Á¤È®ÇÏ°Ô ±¸º°ÇÏ°í ¼¼Æ÷ ³» ÇÁ·ÎÆÄÀÏÀ» Á¶»çÇÒ ¼ö ÀÖ½À´Ï´Ù. Æ÷¸£¸»¸° °íÁ¤, ÆÄ¶óÇÉ ¿Î½º Æ÷¸Å, µ¿°á, ¼¼Æ÷ÇРǥº»¿¡ »ç¿ëµÇ¸ç, À¯ÀüÀÚ ¹ßÇö ¿¬±¸ ¹× ¾Ï °ËÃâ¿¡ »ç¿ëµË´Ï´Ù. ¶ÇÇÑ, Çмú±â°ü ¹× Á¤ºÎ ¿¬±¸±â°ü, Á¦¾àȸ»ç ¹× »ý¸í°øÇÐ ±â¾÷, ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(PCR), ´Ü¹éÁúüÇÐ, Â÷¼¼´ë ½ÃÄö½Ì ¹× ½Ì°Å ½ÃÄö½ÌÀ» À§ÇÑ º´¿ø µî¿¡¼­µµ ÀÀ¿ëµÇ°í ÀÖ½À´Ï´Ù.

·¹ÀÌÀú ĸÃÄ Çö¹ÌÇØºÎ(LCM) ½ÃÀå µ¿Çâ:

»ý¸í°úÇÐ ¿¬±¸½Ç¿¡¼­ÀÇ ºÐÀÚ ºÐ¼®ÀÇ È°¿ë È®´ë°¡ ÇコÄÉ¾î »ê¾÷ÀÇ È®´ë¿Í ÇÔ²² ½ÃÀåÀ» °ßÀÎÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß Çϳª°¡ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, LCMÀº È£ÁöŲº´ÀÇ ¾Ç¼º ¼¼Æ÷ ¹× in situ ¾Ï°ú °°Àº ¼¼Æ÷ Áý´ÜÀ» °í°¨µµ ºÐ¼® ±â¼ú·Î »ýü ³»¿¡¼­ Á¤È®ÇÏ°Ô °Ë»çÇÒ ¼ö Àֱ⠶§¹®¿¡ Àü ¼¼°èÀûÀ¸·Î ¸ÅÃâÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿©·¯ ±¹°¡ÀÇ Á¤ºÎ¿¡ ÀÇÇÑ ÇコÄɾî ÁöÃâ°ú ¿¬±¸°³¹ß(R&D) ÀÚ±ÝÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ¹ýÀÇÇÐ ¹× ºÐÀÚ»ý¹°ÇÐ ¼¾ÅÍ¿¡¼­ ÇØ¼® °¡´ÉÇÑ DNA ÇÁ·ÎÆÄÀÏÀ» ¾ò±â À§ÇÑ LCM¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ÇÔ²² ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ LCMÀº »õ·Î¿î Áø´Ü ¹× ¿¹ÈÄ ¸¶Ä¿¸¦ ½Äº°Çϱâ À§ÇØ Æ¯Á¤ º´¸®ÇÐÀû º´º¯ ¹× ¾Ç¼º ½Å »ý¹°ÀÇ À¯ÀüÀû Áö¹®À» È®¸³ÇÏ´Â µ¥ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¾¾ç¿¡ ´ëÇÑ ¸ÂÃãÇü Ä¡·á¸¦ Á¦°øÇÏ´Â µ¥ µµ¿òÀÌ µÇ¾î ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ½ÃÀå ±â¾÷µéÀº ¹ÙÀÌ¿À¸¶Ä¿ ¹ß°ß ¹× ¾Ï È­ÇÐÀû ¿¹¹æÀ» °³¼±Çϱâ À§ÇØ ¸é¿ª Çü±¤ ·¹ÀÌÀú ´ÙÀÌ¿Àµå¸¦ °®Ãá Çâ»óµÈ LCM ±â¼úÀ» µµÀÔÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» °­È­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • 2024³â ¼¼°è ·¹ÀÌÀú ĸÃÄ Çö¹ÌÇØºÎ(LCM) ½ÃÀå ±Ô¸ð´Â ¾î¶»°Ô µÉ±î?
  • 2025-2033³â ¼¼°è ·¹ÀÌÀú ĸó Çö¹ÌÇØºÎ(LCM) ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • COVID-19°¡ ¼¼°è ·¹ÀÌÀú ĸó Çö¹ÌÇØºÎ(LCM) ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • ¼¼°è ·¹ÀÌÀú ĸó Çö¹ÌÇØºÎ(LCM) ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
  • ¼¼°è ·¹ÀÌÀú ĸÃÄ Çö¹ÌÇØºÎ(LCM) ½ÃÀå ³» ½Ã½ºÅÛ À¯Çüº° ºÐ¼®Àº ¾î¶»°Ô µÇ´Â°¡?
  • ¼¼°è ·¹ÀÌÀú ĸÃÄ Çö¹ÌÇØºÎ(LCM) ½ÃÀåÀÇ ¿ëµµº° ºÐ¼®Àº?
  • ¼¼°è ·¹ÀÌÀú ĸÃÄ Çö¹ÌÇØºÎ(LCM) ½ÃÀåÀÇ ÃÖÁ¾»ç¿ëÀÚº° ºÐ¼®Àº ¾î¶»°Ô µÇ´Â°¡?
  • ¼¼°è ·¹ÀÌÀú ĸó Çö¹ÌÇØºÎ(LCM) ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
  • ¼¼°è ·¹ÀÌÀú ĸÃÄ Çö¹ÌÇØºÎ(LCM) ½ÃÀåÀÇ ÁÖ¿ä Ç÷¹À̾î/±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ·¹ÀÌÀú ĸó Çö¹ÌÇØºÎ(LCM) ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : Á¦Ç°º°

  • ±â±â
  • ¼Ò¸ðǰ
  • ¼ÒÇÁÆ®¿þ¾î¡¤¼­ºñ½º

Á¦7Àå ½ÃÀå ³»¿ª : ½Ã½ºÅÛ À¯Çüº°

  • Àڿܼ± LCM
  • Àû¿Ü¼± LCM
  • ±âŸ

Á¦8Àå ½ÃÀå ³»¿ª : ¿ëµµº°

  • ¿¬±¸¡¤°³¹ß
  • Áø´Ü
  • ±âŸ

Á¦9Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • Çмú±â°ü¡¤Á¤ºÎ ¿¬±¸±â°ü
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • CRO

Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå ³»¿ª : ±¹°¡º°

Á¦11Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • AnaPath Services GmbH(ST Pharm Co. Ltd)
    • Bio-RAD Laboratories Inc.
    • Caresbio Laboratory LLC
    • Carl Zeiss Meditec AG(Carl Zeiss AG)
    • Epistem Ltd
    • Fluidigm Corporation
    • Gnome Diagnostics LLC
    • HUBNER Photonics
    • Leica Microsystems GmbH(Danaher Corporation)
    • Molecular Machines & Industries
    • Thermo Fisher Scientific Inc.
    • VitroVivo Biotech
ksm 25.05.19

The global laser capture microdissection market size reached USD 162 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 346 Million by 2033, exhibiting a growth rate (CAGR) of 8.8% during 2025-2033. The increasing demand for personalized medicines, expanding cancer research, significant growth in biomarker discovery, and advancements in drug development are primarily propelling the market's growth.

Laser capture microdissection (LCM) is a high-resolution method of isolating cells from their surrounding tissues using a laser beam and direct microscopic visualization. It relies on ultraviolet (UV), infrared, and immunofluorescence laser beams to harvest pure enriched cell populations from tissue, blood, and semen samples. It accurately differentiates between normal and abnormal cells to investigate subcellular profiles. It is used on formalin-fixed, paraffin wax-embedded, frozen, and cytologic specimens for studying gene expression and detecting cancer. In addition, it finds application in academic and government research institutes, pharmaceutical and biotechnology companies, polymerase chain reaction (PCR), proteomics, and hospitals for next-generation and sanger sequencing.

Laser Capture Microdissection Market Trends:

The growing utilization of molecular analysis in a bioscience research laboratory, along with the expanding healthcare industry, represents one of the key factors driving the market. Moreover, as LCM allows precise vivo examination of cell populations, such as malignant cells of Hodgkin's disease and carcinoma in situ with sensitive analytical techniques, its sales are rising across the globe. Additionally, there is an increase in healthcare expenditure and research and development (R&D) funding by governments of several countries. This, along with the escalating demand for LCM in forensic science and molecular biology centers to obtain interpretable DNA profiles, is stimulating the market growth. Besides this, LCM is utilized for establishing genetic fingerprints of specific pathological lesions and malignant neoplasms to identify new diagnostic and prognostic markers. It also helps provide individualized treatment of tumor, which is positively influencing the market. Furthermore, key market players are introducing enhanced LCM technologies equipped with immunofluorescence laser diodes for improved biomarker discovery and cancer chemoprevention, which is projected to bolster the growth of the market.

Key Market Segmentation:

Breakup by Product:

  • Instruments
  • Consumables
  • Software and Services

Breakup by System Type:

  • Ultraviolet LCM
  • Infrared LCM
  • Others

Breakup by Application:

  • Research and Development
  • Diagnostics
  • Others

Breakup by End User:

  • Hospitals
  • Academic and Government Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations (CROs)

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AnaPath Services GmbH (ST Pharm Co. Ltd), Bio-RAD Laboratories Inc., Caresbio Laboratory LLC, Carl Zeiss Meditec AG (Carl Zeiss AG), Epistem Ltd, Fluidigm Corporation, Gnome Diagnostics LLC, HUBNER Photonics, Leica Microsystems GmbH (Danaher Corporation), Molecular Machines & Industries, Thermo Fisher Scientific Inc. and VitroVivo Biotech.

Key Questions Answered in This Report

  • 1.What was the size of the global laser capture microdissection market in 2024?
  • 2.What is the expected growth rate of the global laser capture microdissection market during 2025-2033?
  • 3.What has been the impact of COVID-19 on the global laser capture microdissection market?
  • 4.What are the key factors driving the global laser capture microdissection market?
  • 5.What is the breakup of the global laser capture microdissection market based on the system type?
  • 6.What is the breakup of the global laser capture microdissection market based on the application?
  • 7.What is the breakup of the global laser capture microdissection market based on the end user?
  • 8.What are the key regions in the global laser capture microdissection market?
  • 9.Who are the key players/companies in the global laser capture microdissection market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Laser Capture Microdissection Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Instruments
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Consumables
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Software and Services
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by System Type

  • 7.1 Ultraviolet LCM
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Infrared LCM
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Research and Development
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diagnostics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Academic and Government Research Institutes
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Pharmaceutical and Biotechnology Companies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Contract Research Organizations (CROs)
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AnaPath Services GmbH (ST Pharm Co. Ltd)
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Bio-RAD Laboratories Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Caresbio Laboratory LLC
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Carl Zeiss Meditec AG (Carl Zeiss AG)
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Epistem Ltd
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Fluidigm Corporation
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 Gnome Diagnostics LLC
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 HUBNER Photonics
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Leica Microsystems GmbH (Danaher Corporation)
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
    • 15.3.10 Molecular Machines & Industries
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
    • 15.3.11 Thermo Fisher Scientific Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 VitroVivo Biotech
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦